Shots: The BLA submission is based on P-I study and the pivotal P-II DESTINY-Breast01 study. The P-II DESTINY-Breast01 study assessing Trastuzumab deruxtecan in 253 patients with HER2+ unresectable/metastatic breast cancer […]readmore
Tags : (DS-8201)
Shots: The P-II DESTINY-Breast01 study involves assessing of Trastuzumab Deruxtecan (DS-8201) in 253 patients with HER2+ unresectable and/or m-breast cancer prior treated with trastuzumab emtansine The P-II DESTINY-Breast01 study result: […]readmore
![Daiichi Reports Results of [Fam-] Trastuzumab Deruxtecan (DS-8201) in P-I study for HER2 Low Expressing Metastatic Breast Cancer](https://pharmashots.in/wp-content/uploads/2018/12/Daiichi.jpg)
Shots: The P-I study involved assessing of [Fam-] trastuzumab deruxtecan (5.4, 6.4 mg/kg) in 46 patients with heavily pretreated HER2 low expressing metastatic breast cancer P-I study results: ORR (44.2 […]readmore